$600m acquisition bolsters Celgene’s blood cancer portfolio
October 3, 2016Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma
Celgene has shelled out $600m for Swiss biotech EngMab in an effort to reinforce its blood cancer portfolio with a …
Merrimack Pharmaceuticals’ CEO resigns and workforce cut by nearly a quarter
October 3, 2016Sales and Marketing Gary Crocker, Merrimack Pharmaceuticals, Robert Mulroy
Merrimack Pharmaceuticals announced that they would cut away 22% of their workforce and their CEO, Robert Mulroy, would leave immediately …
J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial
October 3, 2016Research and Development, Sales and Marketing AbbVie, Humira, Johnson & Johnson, guselkumab
Johnson & Johnson’s IL-23 drug guselkumab proved to be more effective at clearing moderate to severe cases of the plaque …
Regeneron’s Eylea fails combination study endpoint
October 3, 2016Research and Development, Sales and Marketing Eylea, Regeneron
Regeneron has announced that its eye drug Eylea (aflibercept) failed its primary endpoint in a mid-stage trial investigating its effectiveness …
Novartis reveals impressive four year data upon Cosentyx
October 3, 2016Sales and Marketing Cosentyx, Novartis, psoriasis
Novartis announced on October 1 that Cosentyx (secukinumab) had delivered a high percentage and long-lasting skin clearance in patients with …
GSK agrees to $20m settlement for Chinese bribery allegation
October 3, 2016Business Services, Sales and Marketing China, GSK, GlaxoSmithKline
GlaxoSmithKline has agreed to settle a bribery allegation in China with a payment of $20 million to the US Securities …
Meet SHL at 2016 PDA Universe of Pre-filled Syringes & Injection Devices
October 3, 2016Manufacturing and Production
At this year’s PDA Universe of Pre-filled Syringes & Injection Devices, SHL will be showcasing both new technologies and time-tested …
AstraZeneca agrees $250 million licensing agreement with Allergan
October 3, 2016Sales and Marketing Allergan, AstraZeneca, Crohn’s disease, MEDI2070, MedImmune, crohn's disease
Allergan has entered into a licensing agreement with MedImmune, of AstraZeneca, for the global rights of MedI2070, a synthetic antibody. …
Joanne Beckwith Joins the Clinical Trials Team at Woodley Equipment Company
September 30, 2016clinical research, clinical trials
Woodley Equipment Company Limited is pleased to announce Joanne Beckwith has joined Woodley’s Clinical Trials Division as Logistics Facilitator based at …
Professor David Goldstein appointed as chief adviser for AstraZeneca’s genomics initiative
September 30, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
AstraZeneca today announced that Professor David Goldstein will join the Company in the consultative role of Chief Adviser, Genomics to …
Pharmafocus: Advances in Oncology available now!
September 30, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, oncology, pharmafocus supplement
The latest issue of Pharmafocus is now available, and with it comes Advances in Oncology, our supplement featuring all the …
Top Ten articles in the Pharma Industry this week
September 30, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Coming towards the end of September, we’ve had some major developments in drug trials and bad news for some of …
€10.2 billion lost every year across the EU due to fake medicines
September 30, 2016Manufacturing and Production, Medical Communications EU, European Union Intellectual Property Office, France, Germany, Italy, Spain, united kingdom
A report commissioned by the European Union Intellectual Property Office has shown that a staggering amount of money, €10.2 billion, …
Hanmi Pharma shares crash after shock contract termination
September 30, 2016Manufacturing and Production, Medical Communications, Research and Development Boehringer Ingelheim, Genentech, Germany, HM61713, Hanmi Pharmaceutical, Tagrisso, south korea
News broke on 29 September that Hanmi Pharma, South Korea’s leading drug maker, had signed a $910 million deal with …
NICE rejects Lilly lung cancer drug, recommends Bayer’s Xofigo and Amgen’s Imlygic
September 30, 2016Medical Communications, Sales and Marketing Imlygic, NICE, Portrazza, xofigo
The National Institute of Health and Care Excellence has issued final guidance rejecting Eli Lilly’s Portrazza (necitumumab) for the treatment …
GSK appoints Brian McNamara chief of consumer health division
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brian McNamara, Emma Walmsley, GlaxoSmithKline
GlaxoSmithKline PLC has named Brian McNamara the head of its consumer-health division. The new comes a week after the announcement …
AbbVie opens its $300 million manufacturing plant in Singapore
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Asia, Singapore
AbbVie’s new Singapore based manufacturing plant is expected to be fully operational by late 2018. The plant is expected to …
The October issue of Pharmafocus is now live!
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, Pharmafocus new issue
The latest edition of Pharmafocus is available online now.
Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Johnson & Johnson, Xarelto, phase III, warfarin
The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …
Novo Nordisk to cut 2% of its entire workforce
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Denmark, Novo Nordisk, diabetes, insulin, job cuts, job losses
Novo Nordisk, headquartered in Bagsvaerd, Denmark, has taken the decision to lose 1,000 of its workforce from a total global …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
